Skip to main content
Top
Published in: Clinical Research in Cardiology 3/2017

01-03-2017 | Original Paper

Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study

Authors: Laurent Fauchier, Nicolas Clementy, Arnaud Bisson, Karim Stamboul, Fabrice Ivanes, Denis Angoulvant, Dominique Babuty, Gregory Y. H. Lip

Published in: Clinical Research in Cardiology | Issue 3/2017

Login to get access

Abstract

Background

Atrial fibrillation (AF) may be related to acute and temporary causes, whether cardiovascular or non-cardiovascular. It remains unclear whether the risk of ischemic stroke is different in this setting, and whether antithrombotic management should be different in these patients. The objective of the study was to describe and compare the risk of stroke in AF patients with and with no such temporary precipitating cause.

Methods

Among 8962 patients with AF seen between 2000 and 2010, we focused our analysis on 4587 patients with non-permanent AF, of whom 740 (16 %) had at least one possible temporary cause of AF.

Results

During a mean follow-up of 944 days (median 451, interquartile range 8–1624), the adjusted rates of stroke/TE were non-significantly different between patients with a temporary cause of AF and other AF patients (HR = 1.08, 95 % CI 0.82–1.41, p = 0.59 after adjustment on age, gender, CHA2DS2VASc score, OAC use and antiplatelet therapy use). Cardiovascular mortality was higher in patients with a temporary cause when compared to other AF patients (adjusted HR = 1.42, 95 % CI 1.08–1.86, p = 0.01). In patients with a temporary cause of AF, prescription of oral anticoagulation was independently associated with a better prognosis for cardiovascular death/stroke/thromboembolism (HR = 0.44, 95 % CI 0.29–0.67, p = 0.0001).

Conclusion

AF patients with presumed temporary cause of AF had a similar risk of stroke/thromboembolism and a worse prognosis for cardiovascular mortality than other AF patients. Use of oral anticoagulation was associated with a better prognosis in these patients.
Literature
1.
go back to reference Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867CrossRefPubMed Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857–867CrossRefPubMed
2.
go back to reference Lip GYH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272. doi:10.1378/chest.09-1584 CrossRefPubMed Lip GYH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137:263–272. doi:10.​1378/​chest.​09-1584 CrossRefPubMed
3.
go back to reference Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747. doi:10.1093/eurheartj/ehs253 CrossRefPubMed Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719–2747. doi:10.​1093/​eurheartj/​ehs253 CrossRefPubMed
4.
go back to reference January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76. doi:10.1016/j.jacc.2014.03.022 CrossRefPubMed January CT, Wann LS, Alpert JS et al (2014) 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64:e1–76. doi:10.​1016/​j.​jacc.​2014.​03.​022 CrossRefPubMed
7.
go back to reference Philippart R, Brunet-Bernard A, Clementy N et al (2015) Prognostic value of CHA2DS2-VASc score in patients with “non-valvular atrial fibrillation” and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 36:1822–1830. doi:10.1093/eurheartj/ehv163 CrossRefPubMed Philippart R, Brunet-Bernard A, Clementy N et al (2015) Prognostic value of CHA2DS2-VASc score in patients with “non-valvular atrial fibrillation” and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 36:1822–1830. doi:10.​1093/​eurheartj/​ehv163 CrossRefPubMed
8.
go back to reference Fauchier L, Lecoq C, Clementy N et al (2015) Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest. doi:10.1378/chest.15-1622 Fauchier L, Lecoq C, Clementy N et al (2015) Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: the Loire Valley Atrial Fibrillation Project. Chest. doi:10.​1378/​chest.​15-1622
10.
go back to reference Lip GYH, Andreotti F, Fauchier L et al (2011) Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 106:997–1011. doi:10.1160/TH11-10-0690 CrossRefPubMed Lip GYH, Andreotti F, Fauchier L et al (2011) Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 106:997–1011. doi:10.​1160/​TH11-10-0690 CrossRefPubMed
12.
go back to reference Stamboul K, Zeller M, Fauchier L et al (2015) Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart Br Card Soc 101:864–869. doi:10.1136/heartjnl-2014-307253 Stamboul K, Zeller M, Fauchier L et al (2015) Prognosis of silent atrial fibrillation after acute myocardial infarction at 1-year follow-up. Heart Br Card Soc 101:864–869. doi:10.​1136/​heartjnl-2014-307253
16.
go back to reference Goette A, Nattel S, Kalman J et al (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. doi:10.1093/europace/euw161 Goette A, Nattel S, Kalman J et al (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. doi:10.​1093/​europace/​euw161
18.
go back to reference Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227CrossRefPubMed Page RL, Wilkinson WE, Clair WK et al (1994) Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89:224–227CrossRefPubMed
19.
go back to reference Potpara TS, Polovina MM, Marinkovic JM, Lip GYH (2013) A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 168:4744–4749. doi:10.1016/j.ijcard.2013.07.234 CrossRefPubMed Potpara TS, Polovina MM, Marinkovic JM, Lip GYH (2013) A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. Int J Cardiol 168:4744–4749. doi:10.​1016/​j.​ijcard.​2013.​07.​234 CrossRefPubMed
21.
go back to reference Lip GYH, Skjøth F, Nielsen PB, Larsen TB (2015) Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 114:826–834. doi:10.1160/TH15-07-0565 CrossRefPubMed Lip GYH, Skjøth F, Nielsen PB, Larsen TB (2015) Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 114:826–834. doi:10.​1160/​TH15-07-0565 CrossRefPubMed
23.
go back to reference Sibley S, Muscedere J (2015) New-onset atrial fibrillation in critically ill patients. Can Respir J J Can Thorac Soc 22:179–182 Sibley S, Muscedere J (2015) New-onset atrial fibrillation in critically ill patients. Can Respir J J Can Thorac Soc 22:179–182
25.
go back to reference Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. doi:10.1016/S0140-6736(13)62343-0 CrossRefPubMed Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383:955–962. doi:10.​1016/​S0140-6736(13)62343-0 CrossRefPubMed
26.
go back to reference Caldeira D, Costa J, Ferreira JJ et al (2015) Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol Off J Ger Card Soc 104:582–590. doi:10.1007/s00392-015-0821-8 CrossRef Caldeira D, Costa J, Ferreira JJ et al (2015) Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysis. Clin Res Cardiol Off J Ger Card Soc 104:582–590. doi:10.​1007/​s00392-015-0821-8 CrossRef
27.
go back to reference Nielsen PB, Lane DA, Rasmussen LH et al (2015) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol Off J Ger Card Soc 104:418–429. doi:10.1007/s00392-014-0797-9 CrossRef Nielsen PB, Lane DA, Rasmussen LH et al (2015) Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. Clin Res Cardiol Off J Ger Card Soc 104:418–429. doi:10.​1007/​s00392-014-0797-9 CrossRef
28.
go back to reference Gorin L, Fauchier L, Nonin E et al (2011) Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140:911–917. doi:10.1378/chest.10-2436 CrossRefPubMed Gorin L, Fauchier L, Nonin E et al (2011) Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140:911–917. doi:10.​1378/​chest.​10-2436 CrossRefPubMed
29.
go back to reference Association European Heart Rhythm, Association European, for Cardio-Thoracic Surgery, Camm AJ et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 12:1360–1420. doi:10.1093/europace/euq350 Association European Heart Rhythm, Association European, for Cardio-Thoracic Surgery, Camm AJ et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 12:1360–1420. doi:10.​1093/​europace/​euq350
30.
go back to reference Sabouret P, Depret-Bixio L, Cotte F-E et al (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol Off J Ger Card Soc 103:887–893. doi:10.1007/s00392-014-0726-y CrossRef Sabouret P, Depret-Bixio L, Cotte F-E et al (2014) Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database. Clin Res Cardiol Off J Ger Card Soc 103:887–893. doi:10.​1007/​s00392-014-0726-y CrossRef
Metadata
Title
Prognosis in patients with atrial fibrillation and a presumed “temporary cause” in a community-based cohort study
Authors
Laurent Fauchier
Nicolas Clementy
Arnaud Bisson
Karim Stamboul
Fabrice Ivanes
Denis Angoulvant
Dominique Babuty
Gregory Y. H. Lip
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Clinical Research in Cardiology / Issue 3/2017
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-016-1040-7

Other articles of this Issue 3/2017

Clinical Research in Cardiology 3/2017 Go to the issue